Optimizing Immunosuppression With Sirolimus in the First Year Posttransplantation: Experience in the United States

Transplantation Proceedings

Volumn 41, Issue 6 SUPPL., 2009, Pages

  Weir, M R ^a   Wali, R K ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CREATININE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; THYMOCYTE ANTIBODY;

ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; GRAFT FAILURE; GRAFT INFECTION; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIFE EXPECTANCY; NEPHROTOXICITY; PRIORITY JOURNAL; RECURRENT DISEASE; UNITED STATES;

DIABETES MELLITUS; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; TIME FACTORS; TREATMENT FAILURE; UNITED STATES;

EID: 67949085327     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.06.096     Document Type: Article

References (19)

1. Webster A.C., Lee V.W., Chapman J.R., et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 81 (2006) 1234
2. Flechner S.M., Zhou L., Derweesh I., et al. The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients. Transplantation 76 (2003) 1729
3. Larson T.S., Dean P.G., Stegall M.D., et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 6 (2006) 514
4. Moore J., Middleton L., Cockwell P., et al. Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis. Transplantation 87 (2009) 591
5. Meier-Kriesche H.U., Schold J.D., Srinivas T.R., et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4 (2004) 378
6. Kasiske B.L., Chakkera H.A., and Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 11 (2000) 1735
7. Meier-Kriesche H.U., Steffen B.J., Hochberg A.M., et al. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 75 (2003) 1341
8. Hariharan S., McBride M.A., Cherikh W.S., et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 62 (2002) 311
9. Hariharan S., Johnson C.P., Bresnahan B.A., et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 342 (2000) 605
10. Gourishankar S., Hunsicker L.G., Jhangri G.S., et al. The stability of the glomerular filtration rate after renal transplantation is improving. J Am Soc Nephrol 14 (2003) 2387
11. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61 (1996) 1029
12. Holloran P.F., Gourishankar S., Vongwiwatana A., et al. Approaching the renal transplant with deteriorating function: progressive loss of renal function is not inevitable. In: Weir M.R. (Ed). Medical Management of Kidney Transplantation (2005), Lippincott Williams & Wilkins, Philadelphia, Penn 389
13. Sollinger H.W. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 60 (1995) 225
14. Weir M.R., Ward M.T., Blahut S.A., et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 59 (2001) 1567
15. Weir M.R., Blahut S., Drachenburg C., et al. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. Am J Nephrol 24 (2004) 379
16. Wali R.K., Mohanlal V., Ramos E., et al. Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. Am J Transplant 7 (2007) 1572
17. Diekmann F., Budde K., Oppenheimer F., et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 4 (2004) 1869
18. Kalil R.S., Pearson T.C., Mulgaonkar S., et al. Final 1-year outcomes of the Spare-the-Nephron (STN) trial: mycophenolate mofetil (MMF)-based regimen combined with sirolimus (SRL) to preserve renal function in renal transplantation. J Am Soc Nephrol 19 (2008) 10A
19. Schena F.P., Pascoe M.D., Alberu J., et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 87 (2009) 233